Product image of Miflonide Breezhaler (Budesonide) supplied by GNH India

Miflonide Breezhaler

Active Ingredient:
Budesonide
Origin:
EU

Miflonide Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonide Breezhaler, is a corticosteroid presented as an inhalation powder (dry powder inhaler) for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and children as prescribed, reducing airway inflammation and helping maintain lung function.

GNH India supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Miflonide Breezhaler contains budesonide, an inhaled corticosteroid that acts on the airways to control inflammation in respiratory diseases.

  • Asthma: improves symptom control and reduces the frequency of exacerbations.
  • Chronic obstructive pulmonary disease (COPD): decreases symptoms and lowers the risk of flare‑ups.
  • Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

How It Works

  • Budesonide binds to intracellular glucocorticoid receptors in airway epithelial and inflammatory cells, altering gene transcription. This modulates the production of cytokines, chemokines and other mediators, leading to reduced inflammatory cell infiltration, decreased mucus production, and restoration of normal airway tone, thereby improving airflow.

Side Effects

Budesonide inhalation may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Oral candidiasis (thrush): fungal infection of the mouth.
  • Hoarseness or dysphonia: voice changes after inhalation.
  • Cough or throat irritation: irritation of the upper airway.
  • Headache: mild to moderate head discomfort.
  • Sore throat: irritation of the pharynx.
  • Upper respiratory tract infection: mild viral symptoms.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: sudden worsening of breathing.
  • Adrenal suppression: reduced endogenous cortisol production.
  • Pneumonia: lower respiratory infection, especially in COPD.
  • Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
  • Immunosuppression: increased susceptibility to infections.
  • Decreased bone mineral density: risk of osteoporosis with long‑term use.

Precautions & Warnings

When prescribing or using Miflonide Breezhaler, consider the following safety measures.

  • Assess infection risk: monitor for signs of respiratory infections.
  • Monitor growth in children: long‑term use may affect growth velocity.
  • Avoid abrupt discontinuation: taper dose to prevent adrenal insufficiency.
  • Rinse mouth after inhalation: reduces risk of oral candidiasis.
  • Adjust dose in hepatic impairment: consider reduced systemic exposure.
  • Store at room temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Budesonide may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Ketoconazole: potent CYP3A4 inhibitor that can increase systemic budesonide levels.
  • Ritonavir: strong CYP3A4 inhibitor, may raise exposure and risk of side effects.
  • Rifampicin (and other strong CYP3A4 inducers): can markedly reduce budesonide effectiveness.

Moderate Interactions (Monitor Closely)

  • Short‑acting beta‑agonists: may increase risk of tremor or palpitations.
  • Anticholinergic agents: additive anticholinergic effects may occur.
  • Theophylline: possible increase in plasma concentrations, requiring monitoring.

Frequently Asked Questions

Miflonide Breezhaler contains budesonide, an inhaled corticosteroid that is used to manage chronic airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). It helps improve breathing, reduce symptoms, and lower the frequency of disease exacerbations when taken as prescribed by a healthcare professional.

Budesonide binds to glucocorticoid receptors inside airway cells, influencing gene transcription. This action suppresses the production of inflammatory mediators, reduces immune cell infiltration, and limits mucus secretion, thereby decreasing airway swelling and improving airflow.

The appropriate dose of Miflonide Breezhaler is individualized by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Patients should follow the specific instructions provided by their healthcare provider and the product’s patient‑information leaflet.

Safety data for budesonide inhalation during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Miflonide Breezhaler delivers budesonide via a dry‑powder inhaler, offering consistent dose delivery and a favorable safety profile compared with some higher‑potency corticosteroids. Its particle size is optimized for deep lung deposition, and it is generally well tolerated, though individual response and side‑effect risk may vary among different inhaled steroids.

Store the inhaler at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat. Do not expose the device to freezing temperatures, and ensure the mouthpiece remains clean and dry before each use.

The patient inhales the powder by loading a dose into the Breezhaler device, exhaling fully away from the inhaler, sealing the lips around the mouthpiece, and inhaling forcefully and deeply. After each dose, the patient should rinse their mouth with water and spit to reduce the risk of oral thrush.

Serious risks include paradoxical bronchospasm, adrenal suppression, severe allergic reactions (anaphylaxis), and an increased risk of pneumonia in patients with COPD. Patients should be instructed to seek immediate medical attention if they experience sudden worsening of breathing, signs of infection, or any allergic symptoms.

Miflonide Breezhaler is contraindicated in individuals with a known hypersensitivity to budesonide or any component of the inhaler. It should also be avoided in patients who have experienced a severe allergic reaction to inhaled corticosteroids. Clinicians must evaluate each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Budesonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT